Baseline characteristics of the head-to-head studies comparing ranibizumab with bevacizumab.

CATT = The Comparison of Age-related macular degeneration Treatments Trials; IVAN = The Alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularization study; MANTA = The Multicenter Anti-VEGF Trial; GEFAL = The Groupe d'Etude Français Avastin versus Lucentis dans la DMLA néovasculaire (The French Study Group Avastin versus Lucentis for neovascular AMD).Baseline characteristics of the head-to-head studies comparing ranibizumab with bevacizumab.CATT指年龄相关性黄斑变性治疗试验比较（Comparison of Age-related macular degeneration Treatments Trials）；IVAN指年龄相关性脉络膜新生血管中抑制血管内皮生长因子（VEGF）的替代疗法研究（The Alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularization study）；MANTA指多中心抗VEGF试验（Multicenter Anti-VEGF Trial）；GEFAL指法国阿瓦斯汀与卢科尼斯对比治疗新生血管性年龄相关性黄斑变性研究小组研究，其法语全称为Groupe d'Etude Français Avastin versus Lucentis dans la DMLA néovasculaire，英文译名为The French Study Group Avastin versus Lucentis for neovascular AMD。本部分内容为对比雷珠单抗（ranibizumab）与贝伐珠单抗（bevacizumab）的头对头试验的基线特征。